ARVINAS, INC. (ARVN): restructuring charge — Arvinas cuts workforce 33%, reports positive VERITAC-2 data, removes two Phase 3 combo trials

ARVINAS, INC.

2025-Q1 EPS reported $1.14 revenue$188,800,000

Positive topline results from Phase 3 VERITAC-2 trial of vepdegestrant in 2L+ ER+/HER2- metastatic breast cancer; data accepted for ASCO 2025.
Workforce reduction of ~33% across all areas; expects ~$10M in severance costs, substantially complete by end of Q2 2025.
Removed two planned Phase 3 combination trials (first-line with atirmociclib and second-line with CDK4/6 inhibitor) from vepdegestrant plan.
Cash, cash equivalents and marketable securities of $954.3M as of March 31, 2025; runway extended into H2 2028.
ARV-102 Phase 1 data demonstrated blood-brain barrier penetration and >50% LRRK2 reduction in CSF at 60 mg single dose.

item 2.02 item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ARVINAS, INC. announced a restructuring with charges of approximately $10 million affecting all areas of the Company (approximately 33%).

Type: restructuring
Charge: approximately $10 million
Affected area: all areas of the Company
Headcount: approximately 33%

Exact text from the filing

On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will be substantially completed by the end of the second quarter of 2025. The Company expects that it will incur approximately $10 million in costs in connection with the workforce reduction, which consist of severance and other one-time employee termination benefit expenses, which the Company expects to recognize primarily in the second quarter of 2025.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-25-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.